Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowEli Lilly and Co. expanded its alliance with San Diego-based Ambrx Inc., the companies announced today.
Indianapolis-based Lilly will use Ambrx’s protein-optimization technology, called ReCODE, in its efforts to develop biotech drugs. The two companies will try to bring to market drugs for treating metabolic diseases, central nervous system disorders and other conditions.
Lilly will pay Ambrx an initial upfront fee and make ongoing research support payments. Ambrx also may be compensated for reaching certain research and development milestones and, if products resulting from the collaboration are successfully commercialized, additional royalties.
Other terms of the deal were not disclosed. The collaboration builds on an earlier agreement between the companies signed in January.
Please enable JavaScript to view this content.